David Gordon - Bristol Myers Squibb Featured Researcher

David Gordon, PhD, serves as vice president of Cardiovascular and Fibrosis Discovery Biology at Bristol Myers Squibb. In this role, David leads a team that guides the first steps in the drug discovery and development process, working to identify targets for new drugs in cardiovascular and fibrotic diseases. David and his team then work to identify molecules to modulate these targets in a manner required to slow, stop or reverse the disease process, with the hope of eventually moving them forward into clinical trials. 

David has been at Bristol Myers Squibb for over three decades, starting immediately following his post-doctoral fellowship. Prior to his current role, David spent 10 years leading discovery working groups, before moving into the drug discovery management space – focusing on diseases that have suboptimal or no standard of care – where he’s been ever since. 

“The diseases we focus on are serious, progressive diseases of the heart, lung and liver that have a significant impact on quality of life and greatly increase the risk of premature mortality,” he said. “We hope to be able to create a stronger, lasting impact in addressing the unmet need patients face every day.” 

David graduated from the State University of New York (SUNY) Geneseo with a bachelor’s degree in biology. He went on to earn his PhD in pharmacology from SUNY Stony Brook.